OAM
VIVO

Oppenheimer Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Oppenheimer Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-41,797
Closed -$1.27M – 1180
2022
Q2 		$1.27M Sell
41,797
-2,531
-6% -$68.5K 0.02% 602
2022
Q1 		$1.15M Buy
44,328
+6,208
+16% +$148K 0.02% 705
2021
Q4 		$778K Sell
38,120
-6,743
-15% -$129K 0.01% 852
2021
Q3 		$863K Buy
44,863
+344
+0.8% +$6.86K 0.01% 791
2021
Q2 		$987K Sell
44,519
-7,442
-14% -$158K 0.01% 760
2021
Q1 		$1.36M Buy
+51,961
New +$1.24M 0.02% 631

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer Asset Management's VIVO Position: Q3 2022 in Review

Oppenheimer Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 41,797 shares — an estimated $1.27M sold.

Oppenheimer Asset Management first reported a position in VIVO in Q1 2021 and held it in 6 quarters. The position peaked at $1.36M in Q1 2021. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • Oppenheimer Asset Management reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • Oppenheimer Asset Management sold 41,797 Meridian Bioscience Inc shares in Q3 2022, an estimated $1.27M.
  • Oppenheimer Asset Management first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 6 quarters.
  • Oppenheimer Asset Management's Meridian Bioscience Inc position peaked at $1.36M in Q1 2021.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Oppenheimer Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.